Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Curis announces selection of CUDC-907 as development candidate for cancer

Curis, a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company has selected CUDC-907, an orally available, synthetic small molecule inhibitor of phosphatidylinositol-3-kinase and histone deacetylase as a development candidate from its targeted cancer programs.

7 Jan 2011

JMD publishes results of Tissue of Origin Test validation, reproducibility study

Pathwork Diagnostics, Inc., a privately held molecular diagnostics company focused on oncology, announced today that The Journal of Molecular Diagnostics has published the results of a significant Tissue of Origin Test validation and reproducibility study.

6 Jan 2011

Signal Genetics, Caris Life Sciences announce new agreement to commercialize MyPRS tool

Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics' new gene expression profile test for Multiple Myeloma to community-based hematologists/medical oncologists nationwide.

6 Jan 2011

IRIS ships 3,000th iQ200 Automated Urine Microscopy Analyzer to Sarasota Memorial Hospital

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, has shipped its 3,000th iQ200Automated Urine Microscopy Analyzer.

5 Jan 2011

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

SuperGen, Inc. today announced that it has enrolled the first patient in its first in human study of SGI-110, a second-generation hypomethylating agent, in patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

5 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

Kiadis Pharma, Hospira sign license agreement to develop and commercialize ATIR hematology product

Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agreement with Hospira, Inc., a global specialty pharmaceutical company, to develop and commercialize Kiadis Pharma's ATIR™.

5 Jan 2011

Single cancer cell could be detected in future using new test

Soon scientists will be able to detect a single cancer cell among the billions of cells that circulate in the human bloodstream. The method could detect whether the therapy has worked or even show which therapy would work best. The test depends on circulating tumor cells (CTCs) or cancer cells that have detached from the main tumor and are traveling to other parts of the body.

4 Jan 2011

CDK1 protein deactivates EZH2 enzyme that causes cancer spread

By sticking a chemical group to it at a specific site, a protein arrests an enzyme that may worsen and spread cancer, an international research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the January issue of Nature Cell Biology.

4 Jan 2011

Growth hormone may be hazardous for middle aged and older people

A compound which acts in the opposite way as growth hormone can reverse some of the signs of aging, a research team that includes a Saint Louis University physician has shown. The finding may be counter-intuitive to some older adults who take growth hormone, thinking it will help revitalize them.

24 Dec 2010

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

A study was carried out to examine the extent to which quercetin and trans-resveratrol (RSV) prevented inflammation or insulin resistance in primary cultures of human adipocytes treated with tumor necrosis factor-a (TNF-a)-an inflammatory cytokine elevated in the plasma and adipose tissue of obese, diabetic individuals. Cultures of human adipocytes were pretreated with quercetin and trans-RSV followed by treatment with TNF-a. Subsequently, gene and protein markers of inflammation and insulin resistance were measured.

24 Dec 2010

Therapies to target self-renewing population of chemotherapy-resistant cells needed

Leukemia patients whose cancers express higher levels of genes associated with cancer stem cells have a significantly poorer prognosis than patients with lower levels of the genes, say researchers at the Stanford University School of Medicine. The finding is among the first to show that the cancer stem cell hypothesis - which posits that some cancers spring from and are replenished by a small, hardy population of self-renewing cells - can be used to predict outcomes in a large group of patients and one day to tailor treatments in the clinic.

22 Dec 2010

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Biovest International, Inc. today issued the following update in the form of a "Frequently Asked Questions" report in response to the high volume of inquiries received following the Company's recent presentation at the 2010 American Society of Hematology Annual Meeting (ASH 2010) in Orlando, Florida.

21 Dec 2010

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.

21 Dec 2010

Human fetal immune system entirely different from adult immune system

UCSF researchers have shown for the first time that the human fetal immune system arises from an entirely different source than the adult immune system, and is more likely to tolerate than fight foreign substances in its environment.

17 Dec 2010

Bayer's SAFYRAL oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.

17 Dec 2010

Ipsen discontinues development of chimeric compound BIM 23A760 for acromegaly

Ipsen announced today that the preliminary data from the ongoing phase IIb study in patients with acromegaly for its chimeric compound BIM 23A760 does not meet the expected inhibition of growth hormone (GH) and IGF-1 levels after repeat dosing. Preliminary phase IIb data showed a strong dopaminergic activity but only weak evidence of somatostatinergic activity.

15 Dec 2010

Study suggests unexpected role for NLRP3 protein in cancer vaccine development

The promise of vaccines targeted against various types of cancer has raised the hopes of patients and their families. The reality, however, is that these promising treatments are difficult to develop. One of the challenges is identifying a discrete cellular target to stop cancer growth without inactivating the immune system. Scientists at UNC Lineberger Comprehensive Cancer Center report a laboratory finding that has the potential to increase the effectiveness of therapeutic cancer vaccines.

15 Dec 2010

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

"We provide optimal care to breast cancer patients when we treat the underlying biology of their individual tumors," said Steven Shak, MD, chief medical officer of Genomic Health.

14 Dec 2010

PLATO Foundation launches first medical education activity during 33rd CTRC - AACR Symposium

The PLATO Foundation (Physicians Learning And Teaching in Oncology) a newly established 501(c)(3), tax-exempt organization launched its first medical education activity during the 33rd Annual CTRC - AACR San Antonio Breast Cancer Symposium on December 10, 2010, titled, "Controversial Topics in Breast Cancer: Straight Talk with International Experts."

13 Dec 2010

Hematology News and Research

Further Reading

Curis announces selection of CUDC-907 as development candidate for cancer

JMD publishes results of Tissue of Origin Test validation, reproducibility study

Signal Genetics, Caris Life Sciences announce new agreement to commercialize MyPRS tool

IRIS ships 3,000th iQ200 Automated Urine Microscopy Analyzer to Sarasota Memorial Hospital

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Kiadis Pharma, Hospira sign license agreement to develop and commercialize ATIR hematology product

Single cancer cell could be detected in future using new test

CDK1 protein deactivates EZH2 enzyme that causes cancer spread

Growth hormone may be hazardous for middle aged and older people

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

Therapies to target self-renewing population of chemotherapy-resistant cells needed

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Human fetal immune system entirely different from adult immune system

Bayer's SAFYRAL oral contraceptive receives FDA approval

Ipsen discontinues development of chimeric compound BIM 23A760 for acromegaly

Study suggests unexpected role for NLRP3 protein in cancer vaccine development

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

PLATO Foundation launches first medical education activity during 33rd CTRC - AACR Symposium

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News